A QbD Approach In Designing and Evaluation of Piroxicam Transdermal Patches by Using Design Expert Software

Transdermal patches have a high systemic impact and may increase absorption by bypassing hepatic first-pass metabolism. A transdermal therapeutic system allows drugs to be continuously administered into the systemic bloodstream at a predetermined rate through unbroken skin over an extended period of time. When piroxicam (PXM) is taken orally, it can cause headaches, exhaustion, dry mouth, nose, and throat, nausea, vomiting, and sleepiness. It is also insoluble in water, so its allure is tainted by its decomposition. These issues are avoided by using a solvent-casting technique on a mercury surface in PXM matrix-type transdermal patches. In HPMC E50LV and Eudragit RS 100 transdermal patches, glycerine (plasticizer) is produced through solvent evaporation and a film-forming polymer. The FTIR method will be used aesthetics, breadth, weight difference, folding durability, moisture content, tensile strength, and percentage of PXM content were all deemed satisfactory on a physical level. According to the study, PXM release from transdermal patches can be improved by combining HPMC E50LV (400 mg) and Eudragit RS 100 (300 mg) with glycerine as a plasticize